Nicolas Picard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1658274/publications.pdf

Version: 2024-02-01

61	3,043	172457	161849
papers	citations	29	54
		h-index	g-index

66	66	66	3100
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
2	Is inappropriate medication use a major cause of adverse drug reactions in the elderly?. British Journal of Clinical Pharmacology, 2007, 63, 177-186.	2.4	260
3	IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM. Drug Metabolism and Disposition, 2005, 33, 139-146.	3.3	251
4	The Role of Organic Anionâ€“Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2010, 87, 100-108.	4.7	143
5	IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS. Drug Metabolism and Disposition, 2005, 33, 689-695.	3.3	129
6	Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 805-816.	3.5	117
7	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	2.0	102
8	<scp>UGT</scp>1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundamental and Clinical Pharmacology, 2015, 29, 219-237.	1.9	91
9	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	2.0	89
10	Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes. Drug Metabolism and Disposition, 2010, 38, 40-45.	3.3	84
11	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2016, 38, S1-S20.	2.0	78
12	Involvement of UDP-Glucuronosyltransferases UGT1A9 and UGT2B7 in Ethanol Glucuronidation, and Interactions with Common Drugs of Abuse. Drug Metabolism and Disposition, 2013, 41, 568-574.	3.3	73
13	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenetics and Genomics, 2007, 17, 321-330.	1.5	68
14	Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up. Clinical Pharmacology and Therapeutics, 2010, 88, 95-100.	4.7	66
15	Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. Therapeutic Drug Monitoring, 2004, 26, 600-608.	2.0	65
16	CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients. Transplantation, 2011, 91, 652-656.	1.0	59
17	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. Therapeutic Drug Monitoring, 2016, 38, S57-S69.	2.0	54
18	A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. British Journal of Clinical Pharmacology, 2006, 62, 477-484.	2.4	48

#	Article	IF	Citations
19	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenetics and Genomics, 2010, 20, 537-543.	1.5	48
20	Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatographyâ€“Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2006, 28, 274-277.	2.0	46
21	General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: Applications and constraints. Journal of Separation Science, 2009, 32, 3074-3083.	2.5	46
22	Risk of diarrhoea in a longâ€term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele. British Journal of Clinical Pharmacology, 2010, 69, 675-683.	2.4	40
23	Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5. Drug Metabolism and Disposition, 2007, 35, 350-355.	3.3	39
24	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics, 2015, 16, 1119-1134.	1.3	39
25	Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. International Journal of Legal Medicine, 2017, 131, 979-988.	2.2	38
26	Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapie, 2017, 72, 185-192.	1.0	38
27	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 731-743.	3.3	34
28	Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation. PLoS ONE, 2009, 4, e6942.	2.5	34
29	Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase. Clinical Chemistry, 2009, 55, 986-993.	3.2	31
30	Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on Sirolimus In Vitro Metabolism and Trough Concentrations in Kidney Transplant Recipients. Clinical Chemistry, 2013, 59, 1761-1769.	3.2	30
31	Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. Fundamental and Clinical Pharmacology, 2012, 26, 463-472.	1.9	29
32	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenetics and Genomics, 2012, 22, 725-732.	1.5	27
33	Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenetics and Genomics, 2014, 24, 256-262.	1.5	27
34	Pharmacogenetics of immunosuppressants: State of the art and clinical implementationÂâ€“Ârecommendations from the French National Network of Pharmacogenetics (RNPGx). Therapie, 2017, 72, 285-299.	1.0	27
35	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. Transplantation, 2016, 100, 2129-2137.	1.0	25
36	New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. Pharmacogenomics, 2016, 17, 277-296.	1.3	25

#	Article	IF	Citations
37	Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. Journal of Antimicrobial Chemotherapy, 2016, 71, 484-489.	3.0	25
38	Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacological Research, 2017, 121, 138-144.	7.1	25
39	Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica, 2011, 41, 752-757.	1.1	23
40	Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics. Life Sciences, 2019, 231, 116540.	4.3	22
41	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacological Research, 2016, 111, 501-508.	7.1	19
42	Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatographyâ€“tandem mass spectrometry. Analytical Biochemistry, 2012, 427, 52-59.	2.4	17
43	General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. Journal of Separation Science, 2009, 32, 2209-2217.	2.5	16
44	A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. Pharmacogenomics, 2016, 17, 375-391.	1.3	13
45	The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on â€œMycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimusâ€. Xenobiotica, 2013, 43, 836-838.	1.1	10
46	Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. Analytical and Bioanalytical Chemistry, 2015, 407, 3449-3456.	3.7	10
47	Genetic polymorphisms in the immune response: A focus on kidney transplantation. Clinical Biochemistry, 2016, 49, 363-376.	1.9	9
48	Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemotherapy and Pharmacology, 2018, 82, 361-365.	2.3	9
49	Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients. Clinical Pharmacokinetics, 2021, 60, 611-622.	3.5	9
50	IN VITRO STUDY OF MYCOPHENOLIC ACID GLUCURONIDATION. Drug Metabolism and Disposition, 2004, 32, 1524-1524.	3.3	6
51	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. Therapeutic Drug Monitoring, 2016, 38, S80-S92.	2.0	6
52	Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study. BMC Cancer, 2017, 17, 901.	2.6	6
53	Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2019, 41, 121-130.	2.0	6
54	Severe Decrease of Cyclosporine Levels in a Heart Transplant Recipient Receiving the Direct Thrombin Inhibitor Argatroban. Therapeutic Drug Monitoring, 2014, 36, 273-277.	2.0	5

#	Article	IF	Citations
55	MRP4 is responsible for the efflux transport of mycophenolic acid Î²-<scp>d</scp> glucuronide (MPAG) from hepatocytes to blood. Xenobiotica, 2021, 51, 105-114.	1.1	5
56	Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. Therapeutic Drug Monitoring, 2016, 38, 684-692.	2.0	2
57	Does Tacrolimus, in Comparison With Sirolimus, Increase Mycophenolic Acid Exposure in Kidney Transplant Recipients?. Clinical Pharmacology and Therapeutics, 2010, 87, 650-1.	4.7	1
58	Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?. Journal of Interferon and Cytokine Research, 2016, 36, 204-214.	1.2	1
59	Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients. Pharmacogenomics Journal, 2020, 20, 647-654.	2.0	1
60	Some lessons learned from using medium scale genotyping techniques in pharmacogenetic research. Clinical Chemistry and Laboratory Medicine, 2011, 49, 551-2.	2.3	0
61	A comparison of the effect of cyclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. British Journal of Clinical Pharmacology, 2006, .	2.4	0